EP2922827A4 - Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase - Google Patents

Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase

Info

Publication number
EP2922827A4
EP2922827A4 EP13857254.0A EP13857254A EP2922827A4 EP 2922827 A4 EP2922827 A4 EP 2922827A4 EP 13857254 A EP13857254 A EP 13857254A EP 2922827 A4 EP2922827 A4 EP 2922827A4
Authority
EP
European Patent Office
Prior art keywords
bruton
disease
treating
methods
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13857254.0A
Other languages
English (en)
French (fr)
Other versions
EP2922827A2 (de
Inventor
Tom Daniel
Kenichi Takeshita
Kenneth Foon
Jay Mei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Avilomics Research Inc
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Publication of EP2922827A2 publication Critical patent/EP2922827A2/de
Publication of EP2922827A4 publication Critical patent/EP2922827A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP13857254.0A 2012-11-20 2013-11-19 Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase Withdrawn EP2922827A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728701P 2012-11-20 2012-11-20
US201361870720P 2013-08-27 2013-08-27
PCT/US2013/070772 WO2014081712A2 (en) 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
EP2922827A2 EP2922827A2 (de) 2015-09-30
EP2922827A4 true EP2922827A4 (de) 2016-06-08

Family

ID=50776662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13857254.0A Withdrawn EP2922827A4 (de) 2012-11-20 2013-11-19 Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase

Country Status (3)

Country Link
EP (1) EP2922827A4 (de)
TW (1) TW201427667A (de)
WO (1) WO2014081712A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6478989B2 (ja) * 2013-11-07 2019-03-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
EP3179858B1 (de) 2014-08-13 2019-05-15 Celgene Car Llc Formen und zusammensetzungen eines erk-inhibitors
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158571A1 (en) * 2008-06-27 2009-12-30 Avila Therapeutics And Uses Thereof Heteroaryl compounds and uses thereof
WO2011153514A2 (en) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543819T3 (es) * 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX336875B (es) * 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP6147727B2 (ja) * 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158571A1 (en) * 2008-06-27 2009-12-30 Avila Therapeutics And Uses Thereof Heteroaryl compounds and uses thereof
WO2011153514A2 (en) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAN A BURGER ET AL: "The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients", 1 November 2012 (2012-11-01), pages 187, XP002736107, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper47509.html> *
RAJENDRA N DAMLE ET AL: "Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR)", 15 April 2013 (2013-04-15), pages 3531, XP002736105, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/3531.short> DOI: 10.1158/1538-7445.AM2013-3531 *

Also Published As

Publication number Publication date
TW201427667A (zh) 2014-07-16
WO2014081712A2 (en) 2014-05-30
EP2922827A2 (de) 2015-09-30
WO2014081712A3 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EP2770830A4 (de) Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
EP2922827A4 (de) Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
EP2925740A4 (de) Hemmer der bruton-tyrosinkinase
IL266648B (en) A method for treating Parkinson&#39;s disease
IL269511A (en) New therapeutic approaches for treating parkinson&#39;s disease
EP2809673A4 (de) Cyclische moleküle als hemmer der bruton-tyrosinkinase
IL244492A0 (en) Broton tyrosine kinase inhibitors
IL245042A0 (en) Treatment with proton tyrosine kinase inhibitors and immunotherapy
ZA201400012B (en) Inhibitors of bruton&#39;s tyrosine kinase
ZA201308397B (en) Inhibitors of bruton&#39;s tyrosine kinase
ZA201400739B (en) Inhibitors of bruton&#39;s tyrosine kinase
EP2922546A4 (de) Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase
IL236107A0 (en) Treatment of side effects such as motor and movement disorders related to the treatment of Parkinson&#39;s disease
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
PT2959903T (pt) Medicamento para tratar doença ocular
IL231757A0 (en) Treatment of malignant and nonmalignant diseases with ras antagonists
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
EP2922826A4 (de) Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase
IL233572A0 (en) A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson&#39;s disease
EP2892538A4 (de) Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
EP3113779A4 (de) Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
IL241482A0 (en) A method for treating Parkinson&#39;s disease
HK1193358A (zh) 一种治疗疾病或中枢神经系统病症的方法
AU2011900737A0 (en) Methods of Treating a Disease or Condition of the Central Nervous System

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150615

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20160511

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20171114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180327